There are 302 resources available
LBA1 - IL-10 expressing CD19 CAR-T cells induce complete remission and improve long-term protection in relapsed or refractory B-cell hematological malignancies
Presenter: Li Tang
Session: Proffered Paper session
Resources:
Abstract
Chemotherapy improves cancer immunotherapy efficacy
Presenter: Luis Paz-Ares
Session: IO chemo combo is the optimal therapy: Pro vs contra
Resources:
Slides
Webcast
1O - Exploration of Gut Microbiota Biomarkers in Treatment-Naïve Advanced NSCLC Patients Undergoing Chemo-Immunotherapy: Insights from the Phase III trial, JCOG2007 (NIPPON)
Presenter: Taiki Hakozaki
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Chemotherapy is deleterious to the long term survival benefits of cancer immunotherapies
Presenter: David Planchard
Session: IO chemo combo is the optimal therapy: Pro vs contra
Resources:
Slides
Webcast
Optimising cell engineering for cancer therapy
Presenter: Melita Irving
Session: New developments in genetic modification of immune cells
Resources:
Slides
Webcast
Invited Discussant LBA1 and 1O
Presenter: Camille Bigenwald
Session: Proffered Paper session
Resources:
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session
Resources:
Webcast
Naturally occurring T cell mutations enhance engineered T cell therapies
Presenter: Jaehyuk Choi
Session: New developments in genetic modification of immune cells
Resources:
Slides
Webcast
2O - TILs and PD-L1 early dynamics in the randomized Neo-CheckRay phase II trial evaluating neo-adjuvant immuno-radiation and adenosine pathway blockade for early-stage, high risk ER+/HER2- breast cancer (BC)
Presenter: Alex De Caluwe
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: New developments in genetic modification of immune cells
Resources:
Webcast